Immuno-Oncology | Specialty

FDA Approves Nivolumab/Ipilimumab for Frontline RCC

April 16th 2018

The FDA has approved the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.

Adjuvant Pembrolizumab Improves RFS in Stage III Melanoma

April 15th 2018

Adjuvant pembrolizumab (Keytruda) reduced the risk of recurrence or death by 43% in patients with resected, high-risk stage III melanoma, according to phase III results from the EORTC 1325-MG/KEYNOTE-054 trial.

QoL Data Support Durvalumab Use in Locally Advanced NSCLC

April 14th 2018

Durvalumab treatment over 12 months had no negative effect on key symptoms of lung cancer, physical function, global health status, or quality of life in patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following concurrent chemoradiotherapy.

Dr. Garon Discusses the CheckMate-384 Study in NSCLC

April 12th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.

Dr. Garassino on QoL Findings from the FLAURA Study in NSCLC

April 12th 2018

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non–small cell lung cancer.

Frontline Atezolizumab Combo Emerges as Potential New Standard in NSCLC

April 12th 2018

The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.

Atezolizumab Shines in Long-term POPLAR Findings

April 12th 2018

Anti PD-L1 immunotherapy with atezolizumab (Tecentriq) was strongly superior to docetaxel in locally advanced or metastatic non–small cell lung cancer, according to 3-year survival findings from the phase II POPLAR study.

Role of Immunotherapies Emerging in Gastric/GEJ Cancers

April 11th 2018

Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.

Role of Surgery Could Change Following Durvalumab Approval for Stage III NSCLC

April 11th 2018

Benny Weksler, MD, FACS, discusses the use of surgery in a biomarker-driven and drug-dependent era and highlights other cases in which surgery can benefit patients with NSCLC.

Standardization, Simplification Needed for Wider Adoption of Robotic Cystectomy

April 10th 2018

Amit Gupta, MD, discusses the superiority of robotic cystectomy compared with open cystectomies and its relevance in the current treatment landscape of bladder cancer.

Frontline Pembrolizumab Improves Survival at Lower PD-L1 Threshold

April 9th 2018

Single-agent treatment with the PD-1 inhibitor pembrolizumab improved overall survival versus chemotherapy as a frontline treatment for patients with locally advanced or metastatic non–small cell lung cancer and a PD-L1 expression level ≥1%.

UCLA Oncologist Pursues Promise of CSF1R Inhibitor Combos

April 9th 2018

Zev A. Wainberg, MD, discusses data from the pancreatic cancer cohort of a trial evaluating cabiralizumab in combination with nivolumab.

Dr. Brahmer on Side Effects of Immunotherapy for Lung Cancer

April 7th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing adverse events (AEs) of immunotherapy in lung cancer.

Dr. Naidoo on Studies of Immune-Related Adverse Events in Lung Cancer

March 27th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses studies investigating immune-related adverse events for patients with lung cancer.

FDA Grants Nivolumab/Ipilimumab Priority Review for MSI-H/dMMR Colorectal Cancer

March 27th 2018

The FDA has granted a priority review to a supplemental biologics license application for nivolumab plus ipilimumab for the treatment of adult patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Pembrolizumab Plus Mirvetuximab Soravtansine Active in Ovarian Cancer

March 27th 2018

Almost half of patients with platinum-resistant ovarian cancer had objective responses to combination therapy with pembrolizumab plus the antifolate antibody-drug conjugate mirvetuximab soravtansine.

European Panel Backs New Nivolumab Dosing Schedules

March 26th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding the option of a 4-week dosing schedule to the label for nivolumab for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC).

Frontline Atezolizumab Regimen Improves Survival in NSCLC

March 26th 2018

Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel significantly improved overall survival compared with bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.

Dr. Sznol Discusses Advancements in Immunotherapy for RCC

March 24th 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses advancements in immunotherapy for the treatment of patients with renal cell carcinoma.

Immunotherapy Combinations Emerging in NSCLC

March 24th 2018

Chad Pecot, MD, discusses the rapidly growing area of combination immunotherapy in non–small cell lung cancer.